Related Experiment Videos
Danazol increases factor VIII and factor IX in classic hemophilia and Christmas disease
Insights
Danazol, an attenuated androgen, increased clotting factor levels in patients with hemophilia A and B. This hemophilia treatment may reduce bleeding and the need for plasma transfusions.
Area of Science:
- Hematology
- Pharmacology
Background:
- Hemophilia A (classic hemophilia) and Hemophilia B (Christmas disease) are inherited bleeding disorders.
- Current treatments for hemophilia involve factor replacement therapy, which can be costly and require transfusions.
Purpose of the Study:
- To investigate the efficacy of danazol in increasing clotting factor levels in patients with hemophilia.
- To assess the potential of danazol to reduce bleeding complications and the need for plasma products.
Main Methods:
- Four adults with classic hemophilia and one adult with Christmas disease received oral danazol (600 mg/day) for 14 days.
- Clotting factor levels (Factor VIII and Factor IX) were monitored before and during treatment.
Main Results:
- Factor VIII levels in hemophilia A patients increased from 1-3% to 3-8%.
- Factor IX levels in the Christmas disease patient increased from 5% to 14%.
- Increased clotting factor activity was observed within 5-6 days, peaking between 7-13 days, with no adverse effects.
Conclusions:
- Danazol therapy shows potential in increasing clotting factor activity for hemophilia patients.
- This treatment may decrease hemorrhagic tendency and reduce reliance on plasma product transfusions.
- Further controlled clinical trials are necessary to confirm the therapeutic value of danazol for hemophilia.
Abstract:
We gave danazol (600 mg per day orally for 14 days), an attenuated androgen, to four adults with classic hemophilia and one adult with Christmas disease. The levels of factor VIII in the patients with classic hemophilia ranged from 1 to 3 per cent before treatment and rose to 3 to 8 per cent during the treatment period. The level of factor IX in the patient with Christmas disease rose from 5 to 14 per cent. The rise in clotting-factor activity was usually observed within five to six days after the initiation of therapy and peaked between 7 and 13 days. The drug had no untoward effects. During the 70 patient-days of therapy, only two patients required plasma products, each on one occasion. These data suggest that danazol therapy may decrease the hemorrhagic tendency and reduce the need for transfusions of plasma products in classic hemophilia and Christmas disease. Controlled clinical trials will be required to establish its value in these applications.